Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities

IlluminaIllumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR Newswire

ScienceDeepfakes are everywhere. The godfather of digital forensics is fighting back

Endpoints NewsFDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial

Endpoints NewsKrazati fails confirmatory trial in colorectal cancer, putting approval at risk

10x Genomics BlogWhy 10x Genomics Stock Is Surging Today - TipRanks

FierceBiotechAstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal

Endpoints NewsHouse panel calls to ban China trial data from FDA drug trial applications

Endpoints NewsCourt dismisses part of Lilly lawsuit against Empower, some claims can proceed

Endpoints NewsSupreme Court questions how far generics makers can go with 'skinny label' drugs

IlluminaTempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now? - TradingView

MACHEREY-NAGEL GmbH & Co. KGWorld Laboratory Filter Paper - Market Analysis, Forecast, Size, Trends and Insights - IndexBox

Merck KGaAMerck KGaA taps into Remepy’s Hybrid Drug platform - The Pharma Letter